TITLE:
Prostatic Adenomectomy and Comorbidities: Frequency and Management at the Urology Department of the Ignace Deen National Hospital in Conakry
AUTHORS:
Demba Cisse, Alpha Oumar Barry, Morlaye Fatoumata Bangoura, Alimou Diallo, Mamadou Dian Bah, Youssouf Keita, Daouda Kanté, Thierno Mamadou Oury Diallo, Mamadou Bissiriou Bah, Mamadou Diawo Bah, Abdoulaye Bobo Diallo, Oumar Raphiou Bah
KEYWORDS:
Prostatic Hypertrophy, Comorbidities, Conakry University Hospital
JOURNAL NAME:
Open Journal of Urology,
Vol.14 No.4,
April
26,
2024
ABSTRACT: Goal: To determine the type of comorbidity and highlight the complications of adenomectomy and comorbidities. Material and Methods: This is a prospective, descriptive, cross-sectional study lasting six (6) months, from July 1, 2022 to December 31, 2022. Patients with BPH on comorbidity condition taken care of during the study period AND have agreed to participate in the study. Results: During our study, 49 cases of benign prostatic hypertrophy with comorbidities were collected, representing a frequency of 29%. The average age ranges for the patients were 43 - 70 years. The age group most affected was 70 to 79 years old (38.80%). Nocturnal urinary frequency was the main reason for consultation present in all our patients. The most frequent comorbidity was hypertension, i.e. 83.70%. The PSA rate between 4 and 10 was the most represented, i.e. 42.86%. The prostate volume was between 61 and 100 ml in 40.82% of patients. Histology showed that it was a benign adenomatous hypertrophy of the prostate in 85.70% and a prostatic adenomyoma in 14.29%. Trans-bladder adenomectomy alone was the most performed technique, i.e. 49%, followed by trans urethral resection of the prostate, i.e. 38.80%. Retention of urine after removal of the catheter was the most observed complication, i.e. 12.20%. Conclusion: Benign prostatic hypertrophy with comorbidities constitutes a frequent association. Because their presence can affect effectiveness and lead to complications.